Role of methylenetetrahydrofolate reductase gene (MTHFR) 677C>T polymorphism in pediatric cerebrovascular disorders. Academic Article uri icon

Overview

abstract

  • Homozygosity for the methylenetetrahydrofolate reductase (MTHFR) 677C>T mutation (MTHFR TT) has been linked to an increased risk for stroke, coronary artery disease, and migraine headaches. The authors analyzed the potential link between MTHFR 677C>T homozygosity and childhood stroke. A true association might facilitate screening, recurrence risk stratification, and treatment in patients with cerebrovascular disease. They performed a retrospective chart review of children tested for the MTHFR 677C>/T mutation; 533 patients underwent MTHFR testing, and 8% were homozygous for the MTHFR 677C>T mutation. There was no difference in the cohort compared with the prevalence in the general population. This suggests that the MTHFR 677 C>T polymorphism played a minimal role or no role in stroke risk. However, the data suggest that the MTHFR TT genotype may influence migraine susceptibility in children because there was a higher proportion of migraine patients (28.6%) with the MTHFR TT homozygous genotype.

publication date

  • January 26, 2011

Research

keywords

  • Cerebrovascular Disorders
  • Genetic Predisposition to Disease
  • Methylenetetrahydrofolate Reductase (NADPH2)
  • Pediatrics
  • Polymorphism, Genetic

Identity

Scopus Document Identifier

  • 79952650966

Digital Object Identifier (DOI)

  • 10.1177/0883073810381446

PubMed ID

  • 21270470

Additional Document Info

volume

  • 26

issue

  • 3